Updated Jul 16, 2026
Balcom Alexandra has filed 5 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $24.90M.
Alexandra Balcom is a corporate executive known for her roles as Director and Chief Financial Officer at Nuvalent, Inc. and Crescent Biopharma, Inc. She has been involved in the biopharmaceutical industry, focusing on financial management in companies developing targeted cancer therapies.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-15 | NUVL | Nuvalent, Inc. | D — Derivative transaction | 14.3K | — | |
| 2026-07-15 | NUVL | Nuvalent, Inc. | A — Grant or award | 14.3K | $0.00 | |
| 2026-07-15 | NUVL | Nuvalent, Inc. | D — Derivative transaction | 41.1K | — | |
| 2026-07-15 | NUVL | Nuvalent, Inc. | J — Other acquisition / disposition | 44.4K | $124.00 | $5.51M |
| 2026-07-06 | NUVL | Nuvalent, Inc. | S — Open-market sale | 11.4K | $123.58 | $1.41M |
| 2026-07-06 | NUVL | Nuvalent, Inc. | M — Option exercise | 6.0K | $18.93 | $114K |
| 2026-07-06 | NUVL | Nuvalent, Inc. | M — Option exercise | 5.4K | $6.89 | $37K |
| 2026-06-03 | NUVL | Nuvalent, Inc. | S — Open-market sale | 200 | $103.84 | $21K |
| 2026-06-03 | NUVL | Nuvalent, Inc. | S — Open-market sale | 279 | $101.79 | $28K |
| 2026-06-03 | NUVL | Nuvalent, Inc. | S — Open-market sale | 2.6K | $100.65 | $260K |
| 2026-06-03 | NUVL | Nuvalent, Inc. | S — Open-market sale | 3.1K | $99.86 | $313K |
| 2026-06-03 | NUVL | Nuvalent, Inc. | S — Open-market sale | 1.2K | $98.57 | $118K |
| 2026-06-03 | NUVL | Nuvalent, Inc. | S — Open-market sale | 900 | $97.68 | $88K |
| 2026-06-03 | NUVL | Nuvalent, Inc. | S — Open-market sale | 2.2K | $95.99 | $208K |
| 2026-06-03 | NUVL | Nuvalent, Inc. | S — Open-market sale | 960 | $94.87 | $91K |
| 2026-06-03 | NUVL | Nuvalent, Inc. | M — Option exercise | 11.4K | $6.89 | $79K |
| 2026-05-05 | NUVL | Nuvalent, Inc. | S — Open-market sale | 124 | $99.97 | $12K |
| 2026-05-05 | NUVL | Nuvalent, Inc. | S — Open-market sale | 7.4K | $99.29 | $738K |
| 2026-05-05 | NUVL | Nuvalent, Inc. | S — Open-market sale | 3.9K | $98.42 | $381K |
| 2026-05-05 | NUVL | Nuvalent, Inc. | M — Option exercise | 4.3K | $6.89 | $29K |
Alexandra Balcom is a corporate executive known for her roles as Director and Chief Financial Officer at Nuvalent, Inc. and Crescent Biopharma, Inc. She has been involved in the biopharmaceutical industry, focusing on financial management in companies developing targeted cancer therapies.…
5 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 65 open-market sales ($24.90M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Balcom Alexandra profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.